Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,248,528 shares of the company’s stock after acquiring an additional 5,094 shares during the quarter. Johnson & Johnson accounts for about 0.6% of Zurcher Kantonalbank Zurich Cantonalbank’s holdings, making the stock its 22nd largest position. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.05% of Johnson & Johnson worth $202,336,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Meridian Financial Partners LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $1,626,000. Meridian Investment Counsel Inc. raised its position in Johnson & Johnson by 19.6% in the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after acquiring an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Johnson & Johnson by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after acquiring an additional 102,502 shares during the last quarter. Sheaff Brock Investment Advisors LLC grew its position in shares of Johnson & Johnson by 137.2% during the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 43,568 shares of the company’s stock valued at $7,061,000 after acquiring an additional 25,203 shares during the period. Finally, Lmcg Investments LLC increased its stake in shares of Johnson & Johnson by 32.7% during the 3rd quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock worth $14,125,000 after purchasing an additional 21,471 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on JNJ
Johnson & Johnson Price Performance
JNJ opened at $155.39 on Thursday. The stock’s 50 day moving average price is $159.52 and its 200-day moving average price is $156.38. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The stock has a market capitalization of $374.12 billion, a PE ratio of 22.49, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period last year, the company posted $2.66 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 9.93 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.19%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is presently 71.78%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
- Five stocks we like better than Johnson & Johnson
- Canada Bond Market Holiday: How to Invest and Trade
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- How to Use the MarketBeat Stock Screener
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How to Invest in the FAANG Stocks
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.